Followers | 65 |
Posts | 3812 |
Boards Moderated | 0 |
Alias Born | 03/26/2016 |
Monday, September 19, 2022 11:45:20 AM
according to sonn total o s ..pre split...was about 69 mill
today O S is about 5 mill....hope they have news on the horizon.
bio's almost always take it up the a** on reverse splits, unless coupled with awesome news!!.........G L T A
don`t listen to me, don`t have a clue!
Recent SONN News
- Sonnet BioTherapeutics Releases Virtual Investor ‘”What this Means” Segment • GlobeNewswire Inc. • 11/12/2024 02:15:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/08/2024 01:30:38 PM
- Form 424B4 - Prospectus [Rule 424(b)(4)] • Edgar (US Regulatory) • 11/07/2024 02:22:40 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 11/07/2024 05:15:13 AM
- Sonnet BioTherapeutics Announces Pricing of $5.0 Million Underwritten Public Offering Priced At-The-Market Under Nasdaq Rules • GlobeNewswire Inc. • 11/06/2024 06:20:00 PM
- Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 11/06/2024 02:22:54 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/06/2024 01:48:59 PM
- Sonnet BioTherapeutics Announces Issuance of U.S. Patent Covering a Variant IL-18 Incorporated into Two Novel Immunotherapeutic Drug Candidates • GlobeNewswire Inc. • 11/06/2024 01:30:00 PM
- Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 11/04/2024 02:01:21 PM
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 10/28/2024 01:01:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/17/2024 12:50:32 PM
- Sonnet BioTherapeutics Inc. Regains Compliance with Nasdaq • GlobeNewswire Inc. • 10/17/2024 12:45:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/09/2024 12:56:20 PM
- Sonnet BioTherapeutics Inc. Enters into Licensing Agreement with Alkem Laboratories Limited to Develop and Commercialize SON-080 for Diabetic Peripheral Neuropathy (DPN) in India • GlobeNewswire Inc. • 10/09/2024 12:45:00 PM
- Sonnet BioTherapeutics to Receive Non-Dilutive Funding Through New Jersey Tax Certificate Transfer and Australia R&D Tax Incentive Programs • GlobeNewswire Inc. • 10/04/2024 12:30:00 PM
- Sonnet BioTherapeutics Announces Launch of CEO Corner Platform • GlobeNewswire Inc. • 09/30/2024 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/30/2024 12:30:28 PM
- Sonnet BioTherapeutics Announces 1-for-8 Reverse Stock Split • GlobeNewswire Inc. • 09/25/2024 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/18/2024 12:36:17 PM
- Sonnet BioTherapeutics Completes Enrollment in Phase 1 Study of SON-1010 (IL12-FHAB) as a Monotherapy (SB101) for the Treatment of Solid Tumors • GlobeNewswire Inc. • 09/18/2024 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/12/2024 09:15:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/09/2024 08:08:40 PM
- Sonnet BioTherapeutics to Participate in the Virtual Investor Closing Bell Series • GlobeNewswire Inc. • 09/04/2024 01:15:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/30/2024 12:30:39 PM
Avant Technologies and Ainnova Tech Form Joint Venture to Advance Early Disease Detection Using Artificial Intelligence • AVAI • Nov 12, 2024 9:00 AM
Swifty Global Announces Launch of Swifty Sports IE, Expanding Sports Betting and Casino Services in the Irish Market • DRCR • Nov 12, 2024 9:00 AM
Oohvie App Update Enhances Women's Health with Telemedicine and Online Scheduling • HLYK • Nov 11, 2024 8:00 AM
SANUWAVE Announces Record Quarterly Revenues: Q3 FY2024 Financial Results • SNWV • Nov 8, 2024 7:07 AM
DBG Pays Off $1.3 Million in Convertible Notes, which Retires All of the Company's Convertible Notes • DBGI • Nov 7, 2024 2:16 PM
SMX and FinGo Enter Into Collaboration Mandate to Develop a Joint 'Physical to Digital' Platform Service • SMX • Nov 7, 2024 8:48 AM